Related Experiment Video
Updated: May 18, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
PPARγ in Inflammatory Bowel Disease
Vito Annese1, Francesca Rogai, Alessia Settesoldi
1Gastroenterology Unit, Careggi, University Hospital, 50134 Florence, Italy.
Abstract:
Peroxisome proliferator-activated receptor gamma (PPARγ) is member of a family of nuclear receptors that interacts with nuclear proteins acting as coactivators and corepressors. The colon is a major tissue which expresses PPARγ in epithelial cells and, to a lesser degree, in macrophages and lymphocytes and plays a role in the regulation of intestinal inflammation. Indeed, both natural and synthetic PPARγ ligands have beneficial effects in different models of experimental colitis, with possible implication in the therapy of inflammatory bowel disease (IBD). This paper will specifically focus on potential role of PPARγ in the predisposition and physiopathology of IBD and will analyze its possible role in medical therapy.
Insights
Peroxisome proliferator-activated receptor gamma (PPARγ) influences intestinal inflammation and may be key in treating inflammatory bowel disease (IBD). Research explores PPARγ’s role in IBD development and therapeutic potential.
Area of Science:
- Molecular biology
- Gastroenterology
- Immunology
Background:
- Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor involved in regulating cellular processes.
- PPARγ is expressed in the colon, particularly in epithelial cells, and plays a role in modulating intestinal inflammation.
- Dysregulation of PPARγ signaling is implicated in the pathogenesis of inflammatory bowel disease (IBD).
Purpose of the Study:
- To investigate the role of PPARγ in the predisposition and physiopathology of IBD.
- To analyze the therapeutic potential of PPARγ ligands in managing IBD.
Main Methods:
- Review of existing literature on PPARγ function in the colon.
- Analysis of studies investigating PPARγ ligands in experimental colitis models.
- Examination of the interplay between PPARγ, inflammation, and IBD.
Main Results:
- PPARγ ligands, both natural and synthetic, demonstrate beneficial effects in experimental colitis.
- PPARγ activation shows potential for therapeutic intervention in IBD.
Conclusions:
- PPARγ is a significant factor in the regulation of intestinal inflammation and IBD.
- Targeting PPARγ presents a promising therapeutic strategy for inflammatory bowel disease.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Clinical Manifestations

